Solaris Resources Inc. (CVE:SLS – Get Free Report)’s share price traded down 2.7% on Thursday . The stock traded as low as C$5.95 and last traded at C$6.15. 53,313 shares traded hands during mid-day trading, a decline of 60% from the average session volume of 132,199 shares. The stock had previously closed at C$6.32.
Solaris Resources Stock Down 2.7 %
The stock’s fifty day simple moving average is C$6.15 and its 200-day simple moving average is C$6.15.
About Solaris Resources
SELLAS Life Sciences Group, Inc, a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Further Reading
- Five stocks we like better than Solaris Resources
- What Are Treasury Bonds?
- 3 Legacy Tech Companies Reemerging as AI LeadersÂ
- Best Stocks Under $5.00
- Analysts’ Favorite Cybersecurity Stocks: 3 Top Picks
- The Role Economic Reports Play in a Successful Investment Strategy
- Analysts Are Bullish: 3 Tech Giants With Upgraded Price Targets
Receive News & Ratings for Solaris Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solaris Resources and related companies with MarketBeat.com's FREE daily email newsletter.
